Ticker >

Jubilant Pharmova share price

Jubilant Pharmova Ltd.

NSE: JUBLPHARMA BSE: 530019 SECTOR: Pharmaceuticals & Drugs  113k   467   79

703.45
-13.30 (-1.86%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 718.85

Today's Low

₹ 664.05

52 Week High

₹ 740.8

52 Week Low

₹ 318.5

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

11204.63 Cr.

Enterprise Value

11495.14 Cr.

No. of Shares

15.93 Cr.

P/E

0

P/B

4.79

Face Value

₹ 1

Div. Yield

0.71 %

Book Value (TTM)

₹  146.77

CASH

10.99 Cr.

DEBT

301.5 Cr.

Promoter Holding

50.68 %

EPS (TTM)

₹  -1.99

Sales Growth

11.63%

ROE

2.06 %

ROCE

3.67%

Profit Growth

-38.03 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year11.63%
3 Year-36.34%
5 Year-24.52%

Profit Growth

1 Year-38.03%
3 Year-46.24%
5 Year-28.31%

ROE%

1 Year2.06%
3 Year5.8%
5 Year7.37%

ROCE %

1 Year3.67%
3 Year6.62%
5 Year7.61%

Debt/Equity

0.1251

Price to Cash Flow

-172.07

Interest Cover Ratio

5.28330814079033

CFO/PAT (5 Yr. Avg.)

1.27603269827106

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 50.68 0
Dec 2023 50.68 0
Sep 2023 50.68 0
Jun 2023 50.68 0
Mar 2023 50.68 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 73.2535340011177 days.
  • The company has a high promoter holding of 50.68%.

 Limitations

  • The company has shown a poor profit growth of -46.2449913189436% for the Past 3 years.
  • The company has shown a poor revenue growth of -36.3381611853254% for the Past 3 years.
  • Company has a poor ROE of 5.80381083026096% over the past 3 years.
  • Company has negative cash flow from operations of -65.115.
  • The company is trading at a high PE of 0.
  • The company is trading at a high EV/EBITDA of 157.495.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 182.8 199.84 217.4 186.3 175.2
Total Expenditure 184.7 197.66 213.2 185.5 175.9
Operating Profit -1.9 2.18 4.2 0.8 -0.7
Other Income 7.8 13.66 15.9 18.4 19
Interest 5.5 5.7 6.4 7.1 8.3
Depreciation 11.6 11.37 11.4 11.9 12.3
Exceptional Items 0 0 0 0 0
Profit Before Tax -11.2 -1.23 2.3 0.2 -2.3
Tax -5.3 29.63 0.4 0.6 0.1
Profit After Tax -5.9 -30.86 1.9 -0.4 -2.4
Adjusted EPS (Rs) -0.37 -1.94 0.12 -0.03 -0.15

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 3438.61 3139.9 2709.5 725.73 810.12
Total Expenditure 3117.74 2769 2282.44 719.27 806.89
Operating Profit 320.88 370.9 427.06 6.46 3.23
Other Income 78 173.23 47.88 126.16 137.89
Interest 128.96 136.2 101.8 10.99 18.52
Depreciation 86.48 107.4 99.97 36.91 43.25
Exceptional Items 0 -1.7 0 0 0
Profit Before Tax 183.43 298.84 273.17 84.72 79.34
Tax 35.8 -22.3 58.69 4.23 29.46
Net Profit 147.63 321.14 214.48 80.49 49.88
Adjusted EPS (Rs.) 9.27 20.16 13.47 5.05 3.13

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 15.93 15.93 15.93 15.93 15.93
Total Reserves 2324.38 2591.37 1266.52 2423.14 2398.62
Borrowings 1139.57 1327.91 420 174 174
Other N/C liabilities 86.01 122.95 22 -5.1 41.7
Current liabilities 1297.74 1375.23 120.15 252.26 361.19
Total Liabilities 4863.63 5433.39 1844.6 2860.23 2991.44
Assets
Net Block 1491.35 1864.72 127.08 636.51 687.4
Capital WIP 283.82 58.41 0.33 35.26 46.97
Intangible WIP 0 0.68 0 0 0
Investments 1763.89 1764.03 1645.98 1645.75 1656.57
Loans & Advances 18.02 16.03 4.96 13.98 18.59
Other N/C Assets 25.38 7.39 0 2.92 3.04
Current Assets 1281.17 1722.13 66.25 525.81 578.88
Total Assets 4863.63 5433.39 1844.6 2860.23 2991.44
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 183.43 298.84 273.17 84.72 79.34
Adjustment 159.26 103.01 196.45 -48.68 -35.19
Changes in Assets & Liabilities -112.03 -65.06 181.36 -3.42 -91.82
Tax Paid -48.93 -20.03 -42.6 -19.38 -17.45
Operating Cash Flow 181.74 316.76 608.38 -3.55 -65.12
Investing Cash Flow -284.79 -197.71 116.89 93.1 31.07
Financing Cash Flow 85.28 -41.05 -781.65 -107.37 22.51
Net Cash Flow -17.77 78 -56.37 -17.82 -11.53

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 50.68 50.68 50.68 50.68 50.68
hari shanker bhartia 0.23 0.23 0.23 0.23 0.23
hsb trustee company pvt l... 19.00 19.00 19.00 19.00 19.00
jubilant enpro private li... 1.33 1.33 1.33 1.33 1.33
kavita bhartia 0.01 0.01 0.01 0.01 0.01
mav management advisors l... 3.15 3.15 3.15 3.15 3.15
miller holdings pte ltd 3.28 3.28 3.28 3.28 3.28
nikita resources private ... 2.20 2.20 2.20 2.20 2.20
priyavrat bhartia 0.88 0.88 0.88 0.88 0.88
shamit bhartia 0.08 0.08 0.08 0.08 0.08
spb trustee company pvt l... 20.52 20.52 20.52 20.52 20.52
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 49.32 49.32 49.32 49.32 49.32
abakkus emerging opportun... 1.20 1.20 1.20 1.20 1.20
east bridge capital maste... 3.17 3.17 3.17 3.17 3.17
east bridge capital maste... 4.33 4.33 4.33 4.33 4.27
government pension fund g... 3.96 3.96 3.96 3.90 3.76
investor education and pr... 1.24 - - - 1.24
quant mutual fund - quant... - - - 1.07 1.75
rekha jhunjhunwala - - - - 6.64
theleme india master fund... - - - - 1.17
investor education and pr... - - - 1.25 -
rekha rakesh jhunjhunwala... 6.76 6.68 6.68 6.68 -
investor eduction and pro... - 1.24 1.24 - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

USFDA concludes audit at Radiopharmaceutical manufacturing facility of Jubilant Pharmova’s arm25 Apr 2024, 10:14AM Jubilant Pharmova informs about closure of manufacturing operations18 Apr 2024, 10:05AM Jubilant Pharmova informs about updates on acquisition30 Mar 2024, 12:18PM Jubilant Pharmova informs about change in directorate26 Mar 2024, 4:52PM Jubilant Pharmova informs about analyst meeting11 Mar 2024, 12:38PM Jubilant Pharmova informs about updates17 Feb 2024, 11:25AM Jubilant Pharmova informs about updates3 Feb 2024, 2:37PM Jubilant Pharmova informs about communication3 Feb 2024, 12:01PM USFDA concludes audit at Jubilant Pharmova’s step down subsidiary’s solid dosage formulations facility3 Feb 2024, 11:58AM Jubilant Pharmova - Quaterly Results2 Feb 2024, 2:24PM Jubilant Pharmova - Quaterly Results2 Feb 2024, 2:24PM Jubilant Pharmova - Quaterly Results2 Feb 2024, 2:24PM Jubilant Pharmova informs about notice of postal ballot27 Dec 2023, 11:44AM Jubilant Pharmova’s arm receives USFDA’s approval for Technetium Sulfur Colloid Injection 11 Nov 2023, 10:32AM Jubilant Pharmova informs about newspaper publication30 Oct 2023, 4:49PM Jubilant Pharmova - Quaterly Results27 Oct 2023, 2:28PM Jubilant Pharmova - Quaterly Results27 Oct 2023, 2:28PM Jubilant Pharmova - Quaterly Results27 Oct 2023, 2:28PM Jubilant Pharmova informs about presentation19 Jul 2023, 5:09PM Jubilant Pharmova reports 87% fall in Q1 consolidated net profit19 Jul 2023, 3:22PM Jubilant Pharmova - Quaterly Results19 Jul 2023, 2:03PM Jubilant Pharmova - Quaterly Results19 Jul 2023, 2:03PM Jubilant Pharmova - Quaterly Results19 Jul 2023, 2:03PM Jubilant Pharmova informs about outcome of board meeting29 May 2023, 4:28PM Jubilant Pharmova - Quaterly Results29 May 2023, 3:45PM Jubilant Pharmova - Quaterly Results29 May 2023, 3:45PM Jubilant Pharmova - Quaterly Results29 May 2023, 3:45PM Jubilant Pharmova’s arm gets additional loan facility from Government of Canada17 Mar 2023, 4:49PM Jubilant Pharmova informs about communication17 Mar 2023, 10:06AM USFDA classifies Jubilant Pharmova’s API Facility as VAI8 Mar 2023, 3:58PM Jubilant Pharmova informs about appointment of statutory auditors4 Feb 2023, 2:14PM Jubilant Pharmova reports consolidated net loss of Rs 16 crore in Q3FY23 3 Feb 2023, 3:59PM Jubilant Pharmova - Quaterly Results3 Feb 2023, 1:03PM Jubilant Pharmova - Quaterly Results3 Feb 2023, 1:03PM Jubilant Pharmova - Quaterly Results3 Feb 2023, 1:03PM Jubilant Pharmova informs about investor conference call1 Feb 2023, 4:42PM Jubilant Pharmova’s arm receives USFDA’s approval for Technetium Mertiatide Injection1 Feb 2023, 9:47AM Jubilant Pharmova informs about credit rating 27 Dec 2022, 4:30PM Jubilant Pharmova informs about closure of trading window23 Dec 2022, 4:37PM USFDA concludes inspection at Jubilant Pharmova’s API manufacturing facility in Nanjangud14 Dec 2022, 3:30PM Jubilant Pharmova informs about granted stock options17 Nov 2022, 5:02PM Jubilant Pharmova - Quaterly Results21 Oct 2022, 1:44PM Jubilant Pharmova - Quaterly Results21 Oct 2022, 1:44PM Jubilant Pharmova - Quaterly Results21 Oct 2022, 1:44PM Jubilant Pharmova informs about USFDA communication27 Aug 2022, 11:52AM Jubilant Pharmova’s arm gets EIR from USFDA for radiopharmaceuticals manufacturing facility Montreal Canada 27 Aug 2022, 10:06AM USFDA completes audit at Jubilant Pharmova’s step down subsidiary's facility 3 Aug 2022, 11:14AM Jubilant Pharmova informs about outcome of board meeting2 Aug 2022, 2:35PM Jubilant Pharmova - Quaterly Results2 Aug 2022, 12:58PM Jubilant Pharmova - Quaterly Results2 Aug 2022, 12:58PM

Jubilant Pharmova Stock Price Analysis and Quick Research Report. Is Jubilant Pharmova an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Jubilant Pharmova and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Jubilant Pharmova cash from the operating activity was Rs -65.115 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Jubilant Pharmova has a Debt to Equity ratio of 0.1251 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Jubilant Pharmova , the EPS growth was -38.0271099238152 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Jubilant Pharmova has OPM of 0.398214085125976 % which is a bad sign for profitability.
     
  • ROE: Jubilant Pharmova have a poor ROE of 2.05734186218247 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Jubilant Pharmova is Rs 698. One can use valuation calculators of ticker to know if Jubilant Pharmova share price is undervalued or overvalued.
Last Updated on:
Brief about Jubilant Pharmova

Jubilant Pharmova Ltd. Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis

Jubilant Pharmova Ltd. is a leading pharmaceutical company with a strong presence in the global market. In this stock analysis, we will delve into various aspects of the company that would be of interest to long-term stock investors.

Jubilant Pharmova Ltd. Share Price

The share price of Jubilant Pharmova Ltd. reflects the market valuation of the company's stock. It is influenced by various factors such as industry trends, market conditions, and the overall performance of the company. To gain insights into the historical and current stock price, investors can refer to the price chart available on our website. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions.

Jubilant Pharmova Ltd. Balance Sheet

The balance sheet of Jubilant Pharmova Ltd. provides a snapshot of the company's financial health at a given point in time. It presents the company's assets, liabilities, and shareholders' equity. Investors can analyze the balance sheet to assess the company's solvency, liquidity, and financial stability.

Jubilant Pharmova Ltd. Annual Report

Jubilant Pharmova Ltd. publishes an annual report that provides a comprehensive overview of the company's performance throughout the year. It covers key highlights, financial statements, management discussions, and analysis of the business operations. Investors can download the annual reports from our website to gain deeper insights into the company's strategies and prospects.

Jubilant Pharmova Ltd. Dividend

Dividends are a way for companies to distribute a portion of their profits to shareholders. Jubilant Pharmova Ltd. declares dividends periodically based on its financial performance and policies. For information on historical dividends, investors can explore our pre-built screening tools that provide relevant data to aid in their analysis.

Jubilant Pharmova Ltd. Quarterly Results

Jubilant Pharmova Ltd. releases quarterly results to keep investors updated on the company's performance on a shorter time frame. These results include financial statements, management discussions, and insights into the industry dynamics. Investors can access the quarterly results as downloadable documents on our website.

Jubilant Pharmova Ltd. Stock Price

The stock price of Jubilant Pharmova Ltd. is influenced by various factors such as market demand, industry trends, and company-specific developments. By analyzing the stock price, investors can gain insights into market sentiments towards the company's prospects.

Jubilant Pharmova Ltd. Price Chart

Our website provides a comprehensive price chart that allows investors to track the historical performance of Jubilant Pharmova Ltd.'s stock. By analyzing the price movements and trends, investors can make informed decisions regarding their investments. Our website provides pre-built screening tools to help investors analyze stock price and performance.

Jubilant Pharmova Ltd. News

Stay up to date with the latest news and developments related to Jubilant Pharmova Ltd. Our website provides a dedicated section where investors can access news articles, press releases, and industry updates concerning the company.

Jubilant Pharmova Ltd. Concall Transcripts

We understand the importance of access to concall transcripts for investors. Concalls provide valuable insights into the company's performance and future prospects. Investors can obtain and review Jubilant Pharmova Ltd.'s concall transcripts from our website.

Jubilant Pharmova Ltd. Investor Presentations

Jubilant Pharmova Ltd. conducts investor presentations to provide a deeper understanding of its business operations and growth strategies. Our website offers access to these presentations, allowing investors to stay informed about the company's developments and investment opportunities.

Jubilant Pharmova Ltd. Promoters

The promoters of Jubilant Pharmova Ltd. are key stakeholders who have a significant influence on the company's decision-making and overall direction. Investors are encouraged to learn more about the promoters and their track record to assess the company's governance and stability.

Jubilant Pharmova Ltd. Shareholders

Understanding the shareholder base of Jubilant Pharmova Ltd. provides insights into the ownership structure and potential influence on the company's decision-making. Investors can explore our pre-built screening tools to access data and information on the company's shareholders.

In addition to the comprehensive stock analysis provided, Ticker offers premium features and tools. These include DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis. These tools can assist investors in conducting a more in-depth analysis of Jubilant Pharmova Ltd.'s stock and making informed investment decisions.

By providing downloadable annual reports and quarterly results on our website, we aim to facilitate easy access to the information necessary for investors to conduct their analysis.

Jubilant Pharmova Limited ROCE

The Return on Capital Employed (ROCE) measures a company's ability to generate profits from its invested capital. As an investor, understanding this ratio is crucial in evaluating the financial performance of Jubilant Pharmova Limited. Our stock analysis page provides you with the ROCE data for the company, enabling you to make informed investment decisions. You can find this information in the financials table or ratio section above. ROCE helps you assess how efficiently Jubilant Pharmova Limited is utilizing its capital to generate returns.

Jubilant Pharmova Limited EBITDA

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a key metric that sheds light on a company's operational profitability. By considering non-operating factors, EBITDA provides a clearer picture of Jubilant Pharmova Limited's core business performance. Our stock analysis page offers you the EBITDA data for the company, allowing you to assess its operational efficiency. You can find this information conveniently in the financials table or ratio section above.

Jubilant Pharmova Limited DPS

Dividends per Share (DPS) is an essential indicator for investors seeking income from their investments. By providing the DPS data for Jubilant Pharmova Limited, our stock analysis page allows you to evaluate the company's dividend distribution over time. You can access this information in the financials table or ratio section above. DPS is an important metric as it reflects the commitment of Jubilant Pharmova Limited to sharing its profits with shareholders.

Jubilant Pharmova Limited EPS

Earnings per Share (EPS) is a crucial measure of a company's profitability. By presenting the EPS data for Jubilant Pharmova Limited, our stock analysis page enables you to gauge the company's earnings generation on a per-share basis. You can access this information in the financials table or ratio section above. EPS is widely used by investors to assess the financial performance and potential future growth of Jubilant Pharmova Limited.

Read More
X